Logistic and organizational barriers to herpes zoster vaccination in europe: A systematic review.
Barriers
Herpes Zoster
Systematic review
Vaccination
Journal
Vaccine: X
ISSN: 2590-1362
Titre abrégé: Vaccine X
Pays: England
ID NLM: 101748769
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
received:
29
04
2024
revised:
17
06
2024
accepted:
01
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
The Herpes Zoster (HZ) poses a significant public health threat, leading to morbidity and occasional mortality in unvaccinated adults aged 50 and older. With over 95 % of individuals in this age group globally having prior exposure to Varicella-Zoster Virus, a substantial portion of the world's population is susceptible to developing HZ. Without vaccination, individuals reaching 85 years face a 50 % lifetime risk of HZ. Organizational and logistical barriers further hinder vaccination efforts, involving complexities in cost management, demanding vaccine storage requirements, supply limitations, distribution challenges, absence of a streamlined status collection system, and healthcare system deficiencies. A systematic review was conducted on the studies that examined the logistical and organizational barriers to HZ vaccination among frail and older adults, aligning with the PRISMA guidelines. Eligibility criteria focus on English studies in Europe, excluding pediatric or irrelevant populations. Rayyan AI was used for data extraction, and bias was assessed using the AXIS tool. After excluding 841 based on titles and abstracts, 22 publications were selected. A thorough analysis identified 4 studies meeting inclusion criteria, conducted between 2009 and 2022, unveiling several barriers on HZ vaccination: challenges with healthcare professionals, obstacles related to patients' perceptions and knowledge, difficulties in accessibility, structural issues, social dynamics. The study represents a comprehensive examination, emphasizing the need for targeted interventions to overcome these barriers. The findings underscore the urgency of addressing these challenges to enhance vaccination rates and mitigate the public health burden associated with HZ.
Sections du résumé
Background
UNASSIGNED
The Herpes Zoster (HZ) poses a significant public health threat, leading to morbidity and occasional mortality in unvaccinated adults aged 50 and older. With over 95 % of individuals in this age group globally having prior exposure to Varicella-Zoster Virus, a substantial portion of the world's population is susceptible to developing HZ. Without vaccination, individuals reaching 85 years face a 50 % lifetime risk of HZ. Organizational and logistical barriers further hinder vaccination efforts, involving complexities in cost management, demanding vaccine storage requirements, supply limitations, distribution challenges, absence of a streamlined status collection system, and healthcare system deficiencies.
Methods
UNASSIGNED
A systematic review was conducted on the studies that examined the logistical and organizational barriers to HZ vaccination among frail and older adults, aligning with the PRISMA guidelines. Eligibility criteria focus on English studies in Europe, excluding pediatric or irrelevant populations. Rayyan AI was used for data extraction, and bias was assessed using the AXIS tool.
Results
UNASSIGNED
After excluding 841 based on titles and abstracts, 22 publications were selected. A thorough analysis identified 4 studies meeting inclusion criteria, conducted between 2009 and 2022, unveiling several barriers on HZ vaccination: challenges with healthcare professionals, obstacles related to patients' perceptions and knowledge, difficulties in accessibility, structural issues, social dynamics.
Conclusions
UNASSIGNED
The study represents a comprehensive examination, emphasizing the need for targeted interventions to overcome these barriers. The findings underscore the urgency of addressing these challenges to enhance vaccination rates and mitigate the public health burden associated with HZ.
Identifiants
pubmed: 39206078
doi: 10.1016/j.jvacx.2024.100544
pii: S2590-1362(24)00117-7
pmc: PMC11350440
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100544Informations de copyright
© 2024 The Authors. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Clin Infect Dis. 2019 Jul 2;69(2):341-344
pubmed: 30496358
Hum Vaccin Immunother. 2015;11(1):101-7
pubmed: 25483522
Ther Adv Vaccines. 2015 Jul;3(4):109-20
pubmed: 26478818
J Infect Dis. 2020 Aug 4;222(5):798-806
pubmed: 31830250
Hong Kong Med J. 2017 Aug;23(4):365-73
pubmed: 28684648
Clin Infect Dis. 2021 Sep 15;73(6):941-948
pubmed: 33580242
Am J Health Syst Pharm. 2018 Jun 15;75(12):861-869
pubmed: 29880523
Vaccine. 2020 Dec 14;38(52):8264-8272
pubmed: 33229108
PLoS One. 2022 Oct 26;17(10):e0276082
pubmed: 36288357
Ther Adv Vaccines Immunother. 2022 Mar 21;10:25151355221084535
pubmed: 35340552
Clin Microbiol Infect. 2014 May;20 Suppl 5:25-31
pubmed: 24354949
BMJ Open. 2016 Dec 8;6(12):e011458
pubmed: 27932337
Clin Infect Dis. 2010 Jul 15;51(2):197-213
pubmed: 20550454
Clin Infect Dis. 2009 Sep 15;49(6):817-40
pubmed: 19659433
N Engl J Med. 2016 Sep 15;375(11):1019-32
pubmed: 27626517
N Engl J Med. 2013 Jul 18;369(3):255-63
pubmed: 23863052
J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S429-S442
pubmed: 34590136
BMJ Open. 2014 Jun 10;4(6):e004833
pubmed: 24916088
Expert Rev Vaccines. 2019 Aug;18(8):793-811
pubmed: 31318605
PLoS One. 2019 Aug 1;14(8):e0220230
pubmed: 31369608
Vaccine. 2021 Jun 11;39(26):3520-3527
pubmed: 34023136
N Engl J Med. 2015 May 28;372(22):2087-96
pubmed: 25916341
Hum Vaccin Immunother. 2021 Mar 4;17(3):731-737
pubmed: 32703071
BMJ Glob Health. 2020 Oct;5(10):
pubmed: 33097547
Hum Vaccin Immunother. 2021 Nov 2;17(11):4163-4170
pubmed: 34370590
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
Ann Intern Med. 2010 May 4;152(9):555-60
pubmed: 20439573
J Infect Dis. 2008 Mar 1;197 Suppl 2:S216-23
pubmed: 18419400
Hum Vaccin Immunother. 2015;11(5):1157-64
pubmed: 25806911
Psychol Sci Public Interest. 2017 Dec;18(3):149-207
pubmed: 29611455
BMC Infect Dis. 2017 May 18;17(1):353
pubmed: 28521810
Expert Rev Vaccines. 2021 Sep;20(9):1147-1152
pubmed: 34287096
Syst Rev. 2022 Apr 26;11(1):78
pubmed: 35473819
Vaccine. 2024 Apr 30;42(12):2966-2974
pubmed: 38582693
N Engl J Med. 2007 Mar 29;356(13):1338-43
pubmed: 17392303
N Engl J Med. 2014 Oct 16;371(16):1526-33
pubmed: 25317872
BMC Public Health. 2015 Feb 27;15:193
pubmed: 25880058
Clin Infect Dis. 2001 Jul 1;33(1):62-9
pubmed: 11389496
Vaccine. 2009 Jan 7;27(2):192-6
pubmed: 18996427
Vaccines (Basel). 2022 Oct 21;10(10):
pubmed: 36298636